CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 2.7% - Time to Sell?

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report)'s share price fell 2.7% on Monday . The stock traded as low as $41.14 and last traded at $42.23. 609,124 shares traded hands during mid-day trading, a decline of 70% from the average session volume of 1,997,774 shares. The stock had previously closed at $43.42.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CRSP. Chardan Capital reissued a "buy" rating and issued a $94.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Bank of America cut their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. Barclays reduced their price target on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating for the company in a research report on Wednesday, November 6th. Needham & Company LLC restated a "buy" rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, January 14th. Finally, StockNews.com upgraded shares of CRISPR Therapeutics to a "sell" rating in a research note on Monday, December 30th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $78.38.

CRISPR Therapeutics Stock Down 1.1 %

The company has a market cap of $3.55 billion, a price-to-earnings ratio of -14.70 and a beta of 1.68. The business has a fifty day simple moving average of $43.76 and a 200 day simple moving average of $47.16.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The firm had revenue of $0.60 million during the quarter, compared to analysts' expectations of $6.65 million. During the same quarter last year, the business earned ($1.41) earnings per share. Equities analysts anticipate that CRISPR Therapeutics AG will post -5.1 EPS for the current fiscal year.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the business's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the sale, the chief executive officer now directly owns 181,540 shares in the company, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.10% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Highline Wealth Partners LLC acquired a new stake in CRISPR Therapeutics in the 4th quarter valued at about $39,000. Western Pacific Wealth Management LP grew its position in shares of CRISPR Therapeutics by 100.0% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after purchasing an additional 500 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $40,000. Darwin Wealth Management LLC acquired a new position in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $43,000. Finally, Eastern Bank purchased a new stake in CRISPR Therapeutics in the 3rd quarter valued at approximately $70,000. Institutional investors and hedge funds own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.